Exploring Pro-Tumor Inflammation can unlock a new level of understanding of one of the drivers of cancer1-4

 

What Is Pro-Tumor Inflammation (PTI)?

Pro-Tumor Inflammation (PTI) refers to a type of unregulated inflammation that may have many possible downstream consequences, such as facilitating tumor growth, tumor survival, and the development of metastasis in certain cancers. PTI is also believed to help suppress the immune response against the tumor by altering the tumor microenvironment.1-4

Normal Inflammation vs PTI

Inflammation is the immune system’s normal response to infections and disease5-7

Image illustrating normal inflammation

But what happens when inflammation doesn’t subside?

  1. When not properly regulated, inflammation can become unhealthy3
  2. Unregulated inflammation has been linked to cancer8
  3. There is preliminary evidence that PTI, a type of unregulated inflammation, plays a potential role in non-small cell lung cancer (NSCLC)1,2,9

Inflammation May Play a Dual Role in Cancer10

It may either help promote tumorigenesis or antitumor response10

Image illustrating PTI as one of the hallmarks of cancer
Adapted with permission from Hanahan D et al, 2011.
aThe original designation in Hanahan was “tumor-promoting inflammation.”10

For more than 150 years, scientists have been exploring the link between unregulated inflammation and cancer. PTI is a type of unregulated inflammation that is recognized as one of the hallmarks of cancer.8,10,13

Disruption of the balance between PTI and antitumor immune response may lead to tumor growth11,12,14

PTI and Its Potential Role in NSCLC9

Preliminary studies have shown that PTI helps alter the microenvironment that enables tumor cell proliferation in many different types of cancer, such as NSCLC.1,2,9

Understand drivers of PTI


Novartis logo

Novartis is proud to be the leader in PTI research

The need for bold and transformative research is urgent, which is why we are relentlessly exploring the role of PTI in lung cancer.

References:
 1. Grivennikov SI, Greten FR, Karin M. Cell. 2010;140(6):883-889.
 2. Greten FR, Grivennikov SI. Immunity. 2019;51(1):27-41.
 3. Fleit HB. Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms. 2014:300-314.
 4. Lu H, Ouyang W, Huang C. Mol Cancer Res. 2006;4(4):221-233.
 5. Ward PA. Fundamentals of Inflammation. 2010:1-16.
 6. Medzhitov R. Cell. 2010;140(6):771-776. 
 7. Akira S, Uematsu S, Takeuchi O. Cell. 2006;124(4):783-801.
 8. Hanahan D. Cancer Discov. 2022;12(1):31-46. 
 9. Millares L, Barreiro E, Cortes R, et al. Lung Cancer. 2018;122:124-130.
10. Hanahan D, Weinberg RA. Cell. 2011;144(5):646-674.
11. Gonzalez H, Hagerling C, Werb Z. Genes Dev. 2018;32:1267-1284.
12. Teng MW, et al. J Clin Invest. 2015;125:3338-3346.
13. Virchow R. Cellular Pathology. 1863:321-355.
14. Ostrand-Rosenberg S, Fenselau C. J Immunol. 2018;200:422-431.